Results
10
Companies with strong growth potential, backed by optimistic outlooks both from analysts and management.
10 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
CDR | zł187.30 | 2.0% | 60.8% | zł18.7b | zł145.78 | PE42.6x | E27.0% | 0.5% | Media | ||
XTP | zł94.10 | -4.9% | -41.7% | zł213.6m | zł152.00 | PS17.9x | E129.2% | n/a | Tech | ||
CTX | zł41.80 | -11.8% | -57.8% | zł194.9m | zł121.13 | PS10.1x | E71.2% | n/a | Pharmaceuticals & Biotech | ||
GPP | zł57.60 | -10.7% | -4.0% | zł3.9b | zł68.71 | PE20.9x | E20.2% | 3.5% | Commercial Services | ||
SHO | zł39.80 | -4.3% | 21.7% | zł1.1b | zł50.95 | PE34.2x | E26.6% | 1.7% | Software | ||
VGO | zł408.00 | -0.2% | -20.0% | zł356.9m | zł537.43 | PS4.7x | E50.6% | 0% | Tech | ||
VRC | zł121.00 | 0.8% | 58.8% | zł2.7b | zł124.38 | PE31.8x | E21.9% | 1.3% | Software | ||
CMR | zł331.00 | 0% | 61.5% | zł2.7b | zł267.00 | PE42.1x | E28.5% | 1.5% | Software | ||
SLV | zł47.25 | -10.5% | -21.9% | zł867.3m | zł62.15 | PE16x | E21.1% | n/a | Pharmaceuticals & Biotech | ||
APT | zł16.48 | -2.8% | 9.9% | zł478.7m | zł20.80 | PE11.1x | E21.0% | 3.6% | Tech |